Andreas Goppelt

Title: Innovations by Andreas Goppelt

Introduction

Andreas Goppelt is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biomedical research, particularly in the area of wound healing and diabetes treatment. With a total of 3 patents to his name, Goppelt's work is recognized for its potential impact on healthcare.

Latest Patents

Goppelt's latest patents include innovative methods for utilizing alpha 1-antichymotrypsin (ACT) polypeptides and nucleic acids encoding them. One of his inventions focuses on the treatment and prevention of diabetes-associated and arterial poorly healing wounds. This patent outlines the use of ACT polypeptides for diagnosing and treating wounds that heal poorly, as well as for identifying pharmacologically active substances that influence ACT expression or function. Another patent addresses the use of polypeptides or nucleic acids for diagnosing and treating skin disorders and wound healing, emphasizing their role in identifying pharmacologically active substances.

Career Highlights

Andreas Goppelt is currently associated with Switch Biotech AG, where he continues to advance his research and innovations. His work is characterized by a strong focus on the intersection of molecular biology and therapeutic applications. Goppelt's contributions are paving the way for new treatments that could significantly improve patient outcomes in wound care.

Collaborations

Throughout his career, Goppelt has collaborated with esteemed colleagues such as Jörn-Peter Halle and Johannes Regenbogen. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the biomedical field.

Conclusion

Andreas Goppelt's work exemplifies the spirit of innovation in the biomedical sector. His patents and research efforts are crucial in addressing significant health challenges, particularly in wound healing and diabetes management.